Trial Profile
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms REMAIN
- 01 Sep 2023 Planned End Date changed from 31 Aug 2023 to 31 Aug 2024.
- 01 Sep 2023 Planned primary completion date changed from 31 Aug 2023 to 31 Aug 2024.
- 13 Dec 2022 Primary endpoint (Progression free survival (PFS) has not been met according to Results presented at the 64th American Society of Hematology Annual Meeting and Exposition.